UCBJY News and Press, UCB S.A. ADR From 11/12/20

UCB strengthens its gene therapy activities with additional pipeline programs, capabilities and platforms - Acquisition of Handl Therapeutics BV augments UCB's existing early gene therapy pipeline with two research programs, a proprietary adeno-associated virus (AAV) capsid tech...

UCB Showcases Key Rheumatology Data at American College of Rheumatology Convergence 2020 - C-VIEW study results show CIMZIA® (certolizumab pegol) provided reductions in acute anterior uveitis (AAU) flares in patients with axial spondyloarthritis (axSpA) - C-axSpAnd stud...

Bimekizumab Phase 3 Data Shows Superior Skin Clearance Over Humira® in Moderate-to-Severe Psoriasis Patients - Data from the Phase 3 BE SURE study demonstrated that patients treated with investigational IL-17A and IL-17F inhibitor bimekizumab achieved significantly higher P...

UCB and Aetion Announce Agreement to Enhance Real-World Evidence Generation to Advance Value-Based Contracts UCB will utilize Aetion's analytics platform to align with U.S. payers on treatment outcomes and value PR Newswire NEW YORK, Oct. 7, 2020 NEW YORK , ...

UCB Achieves Important Regulatory Milestone for Bimekizumab - The U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have accepted marketing application submissions for bimekizumab for the treatment of adults with moderate to severe plaque psoriasis ...

Quick Take Inhibikase Therapeutics ( IKT ) intends to raise $25 million from the sale of its common stock in an IPO, according to an amended registration statement . The company is advancing a pipeline of treatment candidates for neurodegenerative and cancer diseases. IKT is still at a ...

ATLANTA , Aug. 31, 2020 /PRNewswire/ -- UCB, a global biopharmaceutical company, today announced the publication of the Phase 3 study results of VIMPAT ®  (lacosamide) CV as adjunctive treatment for uncontrolled primary generalized tonic-clonic seizures (PGTCS), in the ...

- UCB to provide to Roche and Genentech exclusive, world-wide license to UCB's UCB0107, an innovative anti-Tau antibody treatment - UCB will receive an initial upfront payment and, after positive completion of proof-of-concept in Alzheimer's Disease, is eligible to receive further potentia...

UCB SA (UCBJF) Q2 2020 Earnings Conference Call July 27, 2020 8:00 AM ET Company Participants Antje Witte - Vice President Investor Relations Jean-Christophe Tellier - Chief Executive Officer and Executive Director Iris Löw-Friedrich - Chief Medical Officer Emmanuel Caeyma...

The following slide deck was published by UCB SA in conjunction with their 2020 Q2 earnings Read more ...